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ABSTRACT 
Objective: To evaluate association of CYP2D6*10 polymorphism with respect to demographic characteristics (age at onset, genders and weight), 
numerical rating scale (NRS) for measuring pain intensity in relation with resting and movement associated pain and adverse drug effects of PHN 
patients receiving tramadol therapy. 
Methods: Total 246 patients of PHN (148 males and 98 females) were selected who fulfilled the inclusion/exclusion criteria. Clinicians were 
recorded numerical rating scores (at rest and with movement), and note down adverse drug side effects during the time of study. All samples were 
analyzed for CYP2D6*10 polymorphism using PCR-RFLP method.  
Results: We observed genotype distribution of CYP2D6* 10 did not vary significantly with age at onset [non-responders (p=0.317) and responders 
(p=0.260)], genders[ non-responders (p=0.317) and responders (p=0.949)], and weight [non-responders (p=0.298) and responders (p=0.279)] and 
also did not find significant role with respect to resting (p=0.428) and movement associated type of pain (p=0.178). In addition, CYP2D6*10 was not 
associated with adverse effects such as somnolence (p=0.135), dizziness (p=0.178), local site reactions (p=0.535), headache (p=0.502), hypotension 
(p=0.567) and nausea and vomiting (p=0.268) of analgesic therapy. Therefore we conclude that, CYP2D6*10 may not be a predictor of treatment 
outcomes of patients with PHN receiving tramadol.  
Keywords: Post Herpetic Neuralgia, CYP2D6*10 allele, Tramadol, PCR- RFLP, Clinical trial. 
 
INTRODUCTION 
Post herpetic neuralgia (PHN) is the most common complication of 
herpes zoster (HZ) and one of the most challenging to treat. 
Commonly prescribed medications for pain relief of PHN, opioids 
such as tramadol are receiving greater consideration for the 
treatment of PHN type of pain[1,2,3]. Tramadol is a weak μ -opioid 
agonist that also inhibits the reuptake of norepinephrine and 
serotonin. The results of randomized control trials in patients with 
PHN, painful DPN, painful polyneuropathies, PHN of different 
etiologies, and postamputation pain demonstrated that tramadol 
reduced pain and improved some aspects of health-related quality of 
life[1-3,5-7]. But it has developed lots of drug-induced adverse side-
effects such as somnolence, dizziness, local site reaction, headache, 
hypotension, nausea and vomiting [8-10,3,4]. 
Tramadol is metabolized by the CYP2D6 enzyme [11,3,4]. The CYP2D6 
polymorphism has been reported to significantly affect the 
pharmacokinetics of tramadol and also found to be associated with 
variability in opioids efficacy and toxicity [9,12-15]. The variation in 
CYP2D6 activity may impact upon a patient’s pain level and may 
contribute to interindividual variation in their response to opioids[16-
17,3-4]. The CYP2D6 polymorphisms were reported to be associated 
with specific phenotypes such as pain sensitivity [16-18]. This enzyme 
plays a vital role in deciding doses of tramadol in PHN patients. 
The Indian population is interesting with regard to CYP2D6*10 
polymorphism, as India is located midway between the east and the 
west; two populations with clear geographic demarcations in terms 
of polymorphisms. With many drugs that are substrates of CYP2D6, 
the clinical significance may be important. There is, however, a 
dearth of data from India and this study describes a phenotyping 
study in Indian subjects [19]. To test phenotype–genotype 
associations, a larger number of subjects is needed. Owing to cost 
constraints, however, this is usually not possible. The more 
commonly found genotype groups should probably be chosen to 
better infer clinical relevance. They could potentially take advantage 
of the distinctive characteristic of their populations in terms of the 
frequencies of CYP2D6*4 and CYP2D6*10. Such groups may not be 
easily found in other populations in the east or the west [20].The 
prevalence of the PMs phenotype ranges from 0–1% in Asians to 
10% in Caucasians, whereas the prevalence of the UMs phenotype 
ranges from 1–2% in Asians to 29% in some African populations 
[21-23]. The phenotyping studies on South Indians using 
dextromethorphan as a probe drug for the polymorphic drug-
metabolizing enzyme CYP2D6, the proportion of PMs among this 
population was identified. The CYP2D6*10 frequency in Tamilnadu 
was significantly higher compared to that in Kerala, the frequencies 
in Tamilnadu, Kerala, Karnataka, and Andhra Pradesh were 12.9%, 
7.0%, 11.2% and 9.0% respectively[24]. 
Currently, in the Indian scenario, has not been published that 
establish the clinical utility of CYP2D6*10 genotyping in determining 
treatment choice or dose, in relation to tramadol therapy with 
respect to PHN patients. In the present study, we investigated the 
genotype and phenotype frequency of CYP2D6*10 polymorphism in 
tramadol receiving PHN patients. 
MATERIALS AND METHODS 
Study design 
The study was a prospective, non-responders versus responders in 
the treatment of PHN and consisted of oral administration of 
tramadol (short acting) for 4 weeks with day 0 (baseline) 
considered as a baseline. A total of 270 patients were initially 
enrolled for the treatment of which 15 patients did not fit the 
inclusion criteria and 9 patients did not receive tramadol therapy, 
according to the study design. This prospective study included 246 
patients (age group 20-80 years) of PHN patients reported with less 
than 50% pain relief were categorized as “non- responders” (72 
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males and 51 females), and patients reported with 50% pain relief 
after14 day of tramadol treatment were categorized as “responders” 
(76 males, and 47 females). The present study was carried out with 
the help of Pain Clinic, Department of Anesthesiology, Department of 
Dermatology and all molecular biology analysis were carried out in 
Environmental Biochemistry and Molecular Biology Laboratory, 
Department of Biochemistry and Department of Pharmacology at 
University College of Medical Sciences (University of Delhi) & Guru 
Teg Bahadur Hospital, New Delhi- 110095, India during the period 
January 2009 to January 2012. Prior approval of Institutional Ethics 
Committee –Human research was received and patients consent was 
taken in written in the printed Performa. 
In our previous published papers we have already discussed the 
duration of oral tramadol treatment were 4 weeks from day 0 
(inclusion visit) to day 28 (the day before the end visit), dose 
incrementation, inclusion criteria, exclusion criteria, and rescue 
analgesia (topical cream containing 3.33% doxepin and 0.05% 
capsaicin) [2-4]. 
Numerical Rating Scores (NRS) 
On every visit, the intensity of spontaneous pain, including both 
resting and movement associated pain was measured over the past 
24 h on an 11-point NRS. The NRS scoring was entered directly into 
the case record form for each patient [25]. 
PCR-RFLP for CYP2D6*10 polymorphism  
Blood (peripheral lymphocytes) 5 ml was collected from each 
volunteer in ethylenediaminetetraacetic acid (EDTA) coated vials 
and DNA was extracted using Hi- Media mini-preparation kit. 
Genotyping for CYP2D6*10 was performed by Polymerase Chain 
Reaction-Restiction Fragment Length Polymorphism (PCR-RFLP) 
method using specific primer sequences: forward; 5’ 
GTGCTGAGAGTGTCCTGCC 3’and reverse; 5’ 
CACCCACCATCCATGTTTGC 3’. Briefly, the PCR mixture (25 µl) was 
prepared using 50—500 ng of DNA, 2.5 µl of 1X PCR reaction buffer 
(500 mMKCl; 100 mM Tris–HCl; pH 8.3; 5 mM MgCl2), (as supplied 
by the manufacturer), 1 µl of the 2.5 mm dNTPs, each of the 
respective primers at 10 pmol and 0.5U of Taq polymerase 
(Supratherm). All reactions were performed in a thermal cycler 
(Eppendorf Thermal Cyclers). The reaction conditions for CYP2D6*10 
allele was 2 min at 94°
 
C for 1cycle; 30 s at 94°C, 30s at 56°C, and 1 min 
at 72°C for 30 cycles; and 7 min at 72°C for 1 cycle. The fragment of 
*10 allele (325bp) was analyzed in 2% agarose gel (Fig. 1).  
 
Fig. 1: Amplification of CYP2D6*10 allele (2% agarose gel) 
 
Lane M: 100bp Molecular marker; Lane P: Positive control; Lanes: 1-
9: CYP2D6*10 allele (325bp) from samples of PHN patients; Lane: N: 
Negative control 
After the PCR amplification, using Hphl restriction digestion enzyme 
for four hours, samples were analyzed in 1.2% agarose gel and 
stained with EtBr(0.5μg/ml). 100bp DNA molecular weight marker 
was used as a marker to compare the amplimer size of the PCR 
products (Fig. 2). The UMs, EMs, IMs and PMs patients were 
categorized based on genetic analysis (PCR-RFLP Method) [3-4,26-27].  
 
Fig. 2: PCR-RFLP of CYP2D6*10 allele after restriction digestion 
(1.5% agarose gel) 
 
M=100 bp Molecular marker ladder; Lane 1 = PM genotype; Lane 6,= 
IM genotype; Lane 2,3, 4,5,7 = EM genotypes 
Statistical analysis  
The descriptive statistics were expressed as mean ± SD. The 
unpaired t- test was used to compare all mean differences among the 
two groups on day 14. Three factors repeated measure ANOVA was 
applied, taking time as a repeated factor and group and metabolizers 
as a fixed factor. We report multivariate (Wilks‘ Lambda test) 
analysis since the Mauchly‘s test of Sphericity was found, to the 
significant in NRS scores. We report multivariate (Wilks‘ Lambda 
test) analysis since the Mauchly‘s test of Sphericity was found to 
significant in all NRS variables. The Chi - square test was used to find 
the association between onset at ages, genders, weight, adverse 
events with different metabolizers of CYP2D6*10 polymorphism. 
Odds ratios were calculated to test the significance of genotype 
association with the occurrence of PHN. p-values <0.05 were 
considered as significant. The frequency of EMs genotype was 
calculated by adding the total of the EMs genotypes and half of the 
IMs genotypes, which was divided by the total number of 
individuals, the PMs genotype allele frequency was calculated by 
subtracting E allele frequency from 1 (P =1-E). 
RESULTS 
Patient data 
Both the groups of PHN patients were comparable with respect to 
sex, age, weight, duration of disease and gender ratio were found no 
significant (p=0>0.05). In non-responders mean was (males 
53.94±13.24; females 52.45±11.35) and in responders mean was 
(males 53.50±12.72; females 50.17±10.79.33). The mean age (in 
years) of patients in non-responders was 53.33±12.47 and in 
responders was 52.23±12.08. The mean weight (in kg) in non-
responders was 56.28±10.95 and in responders was 51.23±11.45. 
The mean duration of disease (in months) of patients in non-
responders was 4.79±3.48 and in responders was 4.23±4.47. The 
gender ratio (M: F) in non-responders and responders was 72:51 
and 76:47 respectively. 
Demographic charactestics with respect to CYP2D6*10 
polymorphism 
Age  
The primary age of onset for PHN patients were categorized 
according to agewise distibutions (20-40 years), (41-60 years) and 
(61-80 years) respectively. In order to examine the distribution of 
EMs in age wise groups, EMs were found in higher numbers in the 
age group of (41-60 years) [ NR- 41 (50.6%) and R- 45 (51.1%)]. IMs 
were also observed higher in numbers of the age group (41-60 
years) [ NR- 12(40.0%) and R- 18 (60.0%)]. The age groups (20-40 
years) and (61-80 years) a reduced number of EMs and IMs were 
found as compared with age (40-60 years). The PMs were found in 
all age groups. PMs were observed in higher at the age group (41-60 
years) but less numbers were found in (20-40 years) and (61-80 
years). Hence, a significant linear trend was not observed between 
age of onset of the PHN patients. The metabolizers (EMs, IMs and 
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PMs) with respect to the CYP2D6*10 polymorphism was 
insignificantly (p>0.05) between ages at onset in both groups. 
Further, no significant differences were observed in EMs and PMs 
genotype allele frequencies (Table 1). 
Sex 
Although sex differences in the CYP2D6*10 genotype distribution in 
both groups was not evident, male (non-responders) patients had an 
increased frequency of both EMs and IMs genotypes compared with 
female (non-responders) patients, whereas in the responder group 
same observation observed, frequency of EMs and IMs genotypes 
was higher in males than in females. The PMs genotype allele 
frequency was found to be increased in females compared with 
males in both responders and non-responders. The CYP2D6*10 
polymorphism did not vary significantly between gender in both 
groups (p>0.05) (Table 1). 
Weight  
According to weight, stratification of the study group was done on 
the basis of the agewise distribution, i. e., agewise groups (20-40 
years), (41-60 years) and (61-80 years) respectively. Significant 
linear trend was not observed between weight of the PHN patients. 
The metabolizers (EMs, IMs and PMs) compared to the CYP2D6*10 
polymorphism was not significantly (p>0.05) associated with weight 
(Table 1). 
NRS Scores with respect to CYP2D6*10 polymorphism 
Resting Pain Intensity 
The non- responders group shows EMs (n= 81), IMs (n= 30), PMs 
(n= 12) whereas responders having EMs (n= 87), IMs (n= 31), 
PMs (n= 5) respectively. Three factors repeated measures 
ANOVA was carried out to find out interaction between time, 
group and metabolizers. Insignificant (p=0. 428) interaction was 
found among time, group and metabolizers. Similarly with time 
and metabolizers insignificant (p=0. 934) interaction was 
observed in*10 polymorphism. Interaction between the groups 
was found to be significant (p<0.001) indicate that NRS resting 
scores changes with time. (Table 2). 
Movement Associated Pain Intensity  
Three factor repeated measures analysis ANOVA was carried out 
which shows significant interaction with time that means NRS 
movement score changes with the time. Significant interaction 
between the time and metabolizers were found (p=0.098) whereas 
insignificant results were observed between the time, group and 
metabolizers (p=0.178) (Table 2). 
 
Table 1: Demographic characterstics and CYP2D6*10 polymorphism 












20–40 years 16(19.8%) 7(23.3%) 2(16.7%) 0.78 0.22 2.299 0.317 
41–60 years 41(50.6%) 12(40.0%) 6(50.0%) 0.796 0.203 




20–40 years 18(20.5%) 5(16.7%) 2(40.0%) 0.82 0.18 1.270 0.260 
41–60 years 45(51.1%) 18(60.0%) 3(60.0%) 0.796 0.18 




Males 44(61.1%) 23(31.9%) 5(6.9%) 0.778 0.229 2.299 0.317 




Males 55(72.4%) 19(25.0%) 2(2.6%) 0.848 0.151 1.299 0.949 




20–40 years 16 (47.1%) 7(58.3%) 2(50.0%)  2.422 0.298 
41–60 years 41(47.7%) 12(40.0%) 6(66.7%) 




20–40 years 18(52.9%) 5(41.7%) 2(50.0%) 2.550 0.279 
41–60 years 45(52.3%) 18(60.0%) 3(33.3%) 
61–80 years 25(51.0%) 7(38.9%) 0(0.0%) 
NR- Non-responders; R- Responders; All values are expressed in numbers and percentages; N- Numbers; EM-Extensive metabolizers; IM-
Intermediate metabolizers; PM-Poor metabolizers 
 
Table 2: Numerical rating scales (NRS) scores and CYP2D6*10 polymorphism 
NRS Scales Group Metabolizers 0 Day 
(Baseline) 













IM(n=30) 7.87±1.252 6.77±1.331 5.63±1.299 4.77±1.278 2.80±1.095 
PM(n=12) 7.83±1.337 7.08±1.311 5.83±1.115 4.75±.866 2.67±.985 
R 
(n=123) 
EM(n=87) 7.36±1.438 5.90±1.463 4.68±1.289 3.23±1.042 1.66±.790 
IM(n=31) 7.63±1.426 6.07±1.507 4.90±1.373 3.37±.999 1.73±.944 














7.57±1.591 6.70±1.579 5.63±1.671 4.63±1.520 2.67±1.348 
PM(n=12) 7.17±1.642 6.83±1.801 5.75±1.422 4.58±1.311 2.75±1.215 
R 
(n=123) 
EM(n=88) 7.05±1.604 5.65±1.612 4.45±1.381 3.02±.994 1.47±1.028 
IM(n=31) 7.37±1.520 5.80±1.495 4.77±1.524 3.20±1.126 1.53±1.137 
PM(n=5) 5.00±1.225 4.00±.707 2.80±.837 2.00±.707 0.60±.548 
NR- Non- Responders; R-Responders; EM- Extensive metabolizers; IM- Intermediate metabolizers; PM- Poor metabolizers; All values are expressed 
in mean and standard deviation P>0.05- Non significant; a-interaction with time; b-interaction with group (non-responders versus responders);c- 
interaction with metabolizers and group; d- interaction with group (non-responders versus responders), metabolizers and time; Analysis was 
performed by Three Way Repeated measure ANOVA using Wilks’s Lambda test. 
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Table 3: Adverse effects and CYP2D6*10 polymorphism 
Adverse Effects Yes/No Metabolizers Total 
  EM, N (%) IM, N (%) PM, N(%)  
Somnolence No(n=181) 127(70.2%) 45(24.9%) 9(5.0%) 181 
Yes(n=65) 42(64.6%) 15(23.1%) 8(12.3%) 65 
Total(n=246) 169(68.7%) 60(24.4%) 17(6.9%) 246 
Pearson Chi-Square Test p=0.135 
Dizziness No(n=192) 127(66.1%) 52(27.1%) 13(6.8%) 192 
Yes(n=54) 42(77.8%) 8(14.8%) 4(7.4%) 54 
Total(n=246) 169(68.7%) 60(24.4%) 17(6.9%) 246 
PearsonChi-Square Test p=0.178 
Local site reaction No (n=197) 133(67.5%) 51(25.9%) 13(6.6%) 197 
Yes(n=49) 36(73.5%) 9(18.4%) 4(8.2%) 49 
Total(n=246) 169(68.7%) 60(24.4%) 17(6.9%) 246 
Pearson Chi-Square Test p=0.535 
Headache No (n=196) 134(68.4%) 50(25.5%) 12(6.1%) 196 
Yes (n=50) 35(70.0%) 10(20.0%) 5(10.0%) 50 
Total(n=246) 169(68.7%) 60(24.4%) 17(6.9%) 246 
Pearson Chi-Square Test p=0.502 
Hypotension No(n=181) 127(70.2%) 41(22.7%) 13(7.2%) 181 
Yes(n=65) 42(64.6%) 19(29.2%) 4(6.2%) 65 
Total(n=246) 169(68.7%) 60(24.4%) 17(6.9%) 246 
Pearson Chi-Square Test p=0.567 
Nausea and vomiting 
 
No (n=178) 122(68.5%) 41(23.0%) 15(8.4%) 178 
Yes(n=68) 47(69.1%) 19(27.9%) 2(2.9%) 68 
Total(n=246) 169(68.7%) 60(24.4%) 17(6.9%) 246 
Pearson Chi-Square Test p=0.268 
All values are expressed in numbers and percentages; N- Numbers; UM-Ultra metabolizers; EM-Extensive metabolizers; IM-Intermediate 
metabolizers; PM-Poor metabolizers 
 
Adverse effects with respect to CYP2D6*10 polymorphism 
In this study, somnolence was noticed in sixty five patients, out of 
which 42(64.6%) in EMs, 15 (23.1%) patients belong to IMs group 
and 8 (12.3%) PMs both groups. Fifty four patients dizziness was 
observed, out of which 42(77.8%) in EMs, 8(14.8%) in IMs patients 
and PMs was 4(7.4%) in a both groups which lasted from 2-3 days 
and then subsided. Local site reactions found fourty nine and when 
compared to CYP2D6*10 polymorphism showing non-significant 
(p=0.535) using the Chi - square test. The headache was fifty 
patients in both groups. Hypotension was also observed in sixty five 
patients in both groups. The sixty eight patients were observed in 
nausea and vomiting, out of 246 patients in both groups. In all, 
adverse events compared to CYP2D6*10 allele with EMs, IMs and 
PMs shows none significant(p >0.05). The adverse effects for all 
evidence (somnolence (p=0. 135), dizziness (p=0. 178), and local 
site reactions (p=0. 535), headache (p=0. 502), hypotension (p=0. 
567), nausea and vomiting (P=0.268) were showing non-significant 
for all the patients (p>0.05) (Table 3). 
Rescue analgesia with respect to CYP2D6*10 polymorphism 
The one hundred and thirty five patients required rescue analgesia. 
In all, rescue analgesia were compared to CYP2D6*10 polymorphism 
with metabolizers (EMs, IMs and PMs) showing insignificant 
(p>0.05). The CYP2D6*10 allele did not find significant (p=0. 179) 
with respect to rescue analgesia (data not shown). 
DISCUSSION 
In the current study genotype relationship of CYP2D6*10 has not 
been studied in PHN patients in Indian population undergoing 
tramadol treatment. In our previous study, clinically evaluated 
safety and efficacy of oral tramadol therapy using 50 mg to 200 mg 
per day for 4 weeks in PHN patients were studied and results 
observed significant pain reduction in terms of enhanced pain relief, 
reduced sleep interference, greater global improvement, diminished 
side-effect profile, and improved quality of life[2]. Previous genetic 
studies also showed CYP2D6*4, and CYP2D6*2 polymorphisms may 
not be a predictor of treatment outcome in patients with PHN 
receiving tramadol therapy [3,4].  
The striength of the current study is that CYP2D6*10 polymorphism 
was not significantly associated onset at ages, genders and weight 
may not be a predictors of PHN patients. Our previous results 
showed that the CYP2D6*4 and CYP2D6*2 genotype distributions 
and haploid frequencies did not vary significantly among the onset 
at ages, genders, and weight may not be a predictor of PHN [3,4]. 
Wang et al.[28] was observed that, age, gender distribution, duration 
of surgery, height as well as body weight of the patients among the 
postoperative tramadol analgesia in a Chinese population. There was 
no difference in the total analgesic consumption of tramadol between 
patient groups and also there was no significant difference in the 
satisfaction among the CYP2D6 genotypes (p>0.05). Similarly Dworkin 
et al.[29] did not find sex differences to be associated with the various 
aspects of HZ, with the only exception being the intensity of acute pain, 
which is higher in females than in males. Gan et al.[9] also found that 
no difference in terms of gender between groups. Volpi et al.[30] have 
suggested that the female gender is associated with more severe acute 
HZ pain; it was shown in multivariate analysis that gender difference 
was observed by depression, which was found to be more severe and 
more frequent in women compared with men. Finally, female sex has 
been proposed as a predictor of PHN. However, this has not yet 
reached a convincing level of evidence [31-34]. There is evidence that 
PHN is more common in women than in men [35,36]. HZ incidence 
was more common in women than men, a finding supported by 
several other studies, albeit not all [37-41]. 
In this study, CYP2D6*10 genotype–phenotype distribution did not 
vary significantly between ages-at-onset groups. Earlier reported 
CYP2D6*4 and CYP2D6*2 genotype–phenotype distribution did not 
vary significantly between ages-at-onset groups [3,4]. The present 
study has some potential limitations, such as the relatively low 
number of patients examined compared with the number of studied 
predictors [42]. In addition, the results reported in this study 
support the use of analgesic drug (tramadol) prescription based on 
age but also on clinical findings. PHN is an immunocompetent 
disease and at an older age, the immune system weakens. The HZ 
virus attacks the immune system and because of old age damages 
the nerves; this remains to be the best indicator of developing PHN. 
On the other hand, age is the predominant predictor of PHN [43,44]. 
In a UK primary-care study, the prevalence of PHN increased 
markedly with age: from 8% between the ages of 50 and 54 years to 
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21% at the age of 80–84 years[35].PHN has been repeatedly 
associated with older age [30,33,40,45-47]. 
The effect of a drug on the body depends on the combination of 
pharmacokinetic factors. Women have a different volume of 
distribution and clearance than men, which could result in 
differences in effective drug concentrations [48-51]. Female 
patients, being generally lighter in weight and smaller in build than 
their male counterparts but usually receiving the same drug doses 
have been demonstrated to be more prone to ADRs in some studies 
[52-54]. This is most probably attributable to the exposure to higher 
dose per kg body weight for the females. 
The present study demonstrated that, the CYP2D6*10 polymorphism 
did not vary significantly among resting and movement stages on 
the NRS between the groups. The same type of results also found 
previous reported not significantly related to CYP2D6*4 and 
CYP2D6*2 alleles but clinically significant reduction related to 
resting and movement associated pain scale scores [2,3,4]. Jensen et 
al.[55] and McCarthy et al.[56] has shown that, the visual analogue 
scale (VAS) measurement for detecting effects in postoperative pain 
treatment was superior to the verbal rating scale (VRS), or their 
combination. The VAS used in this study, can thus be considered a 
valid score for the assessment of intensity of pain and the analgesic 
efficacy of tramadol. 
Regarding the adverse events encountered in our study, due to 
tramadol therapy in both groups, the most common adverse events 
were somnolence, dizziness, local site reactions, headache, 
hypotension and nausea and vomiting. In the present study, no 
significant association was found between adverse events compared 
with the CYP2D6*10 polymorphism. Also previous genotype studies 
related to adverse events did not find any significant related to 
CYP2D6*4 polymorphism and CYP2D6*2 polymorphism [3,4]. In 
term of adverse effects, UMs were more sensitive to tramadol than 
EMs. They found that UMs volunteers experienced quicker analgesic 
effects but were prone to higher mu-opioid-related toxicity after 
tramadol in experimental pain setting using a cold pressure test 
when they studied 11 carriers of a CYP2D6 duplication allele (UMs) 
and compared with 11 carriers of two active CYP2D6 (EMs). 
Pharmacokinetics and pharmacodynamics effects (pain threshold 
and pain tolerance, miosis and adverse events) were monitored after 
a single dose of 100 mg racemic tramadol, rapid release formulation 
[27] and they observed differences in tramadol adverse effects with 
a higher frequency of nausea (50.0 vs.9.0%) in the UMs compared 
with the EMs. Stamer et al. [14]suggested that, the PMs, non-
response rates to tramadol treatment increased four fold compared 
with the other genotypes. Thus this genotype was associated with 
poor efficacy of tramadol analgesia. Li et al. [57] observed 
association between CYP2D6*10 genetic polymorphisms and the 
pharmacokinetics of tramadol in Chinese volunteers. Wang et 
al.[28]investigated that, CYP2D6 * 10 alleles had an impact on the 
postoperative analgesic effect of tramadol in 70 Chinese patients 
after gastrectomy. Gan et al. [9]was also observed that the incidence 
of vomiting, the IMs were found to have a statistically higher 
incidence of adverse drug reactions when compared with the groups 
that metabolize tramadol faster (UMs and EMs). This shows that the 
slower metabolizers of tramadol tend to experience more adverse 
effects of the drug and also found that there were significant 
differences in the adverse-effect profiles amongst the various 
genotype groups, with the IMs group experiencing more adverse 
effects than the EMs, and the EMs having more adverse effects than the 
UMs. It also CYP2D6 activity may play an important role in determining 
the pharmacokinetics of tramadol and in predicting it’s adverse. Other 
studies found no difference in term of adverse events such as nausea and 
vomiting between patients with CYP2D6 UMs phenotype, PMs 
phenotype or reduced CYP2D6 activity and EMs [15,28,58]. 
CONCLUSION 
In conclusion, to the best of our knowledge, this is the first study 
reporting genotype- relationship with PHN patients in Indian 
population. Assessment of CYP2D6*10 metabolic status before 
initiation of therapy may not help to identify patients at risk for no 
response to therapy or toxic drug effects and is needed to ensure 
optimal dosing recommendations. 
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